February 09 2022
Philadelphia, PA – February 9, 2022 – Today, NRG Oncology announced that the first participant has been enrolled to the colorectal cancer prevention trial, FORTE, NRG-CC005 by an NRG NCORP site. FORTE (Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps) is a large, randomized trial of surveillance colonoscopy for participants with a first-time diagnosis of 1 or 2 small benign polyps, called adenomas. Participants in the study will be assigned to having their next colonoscopy exam at 5 years and at 10 years or their next colonoscopy exam at 10 years. The study is expected to enroll 9,500 participants (about 4,750 people in each study group).
The primary objective of the study is to determine whether people who had 1 or 2 small benign polyps removed during colonoscopy should have their repeat colonoscopy exam at 10 years or should they have their repeat exams at both 5 years and at 10 years.
According to Robert E. Schoen, MD, MPH, Chief, Division of Gastroenterology, Hepatology and Nutrition at the University of Pittsburgh and the University of Pittsburgh Medical Center (UPMC) and Principal Investigator for FORTE, “The best timing for a repeat colonoscopy for people with 1 or 2 small benign polyps removed during colonoscopy is uncertain. Colonoscopy is neither fun nor risk free. Determining the proper timing for follow up testing is an important goal and impacts a huge number of U.S. adults.”
For more information about the FORTE study, please visit our participant-directed information available on the NRG Oncology website: FORTE Study.
About NRG Oncology and NRG NCORP
NRG Oncology seeks to improve the lives of those at risk for or impacted by cancer. NRG Oncology conducts clinical research through its multi-national member network with a goal to conduct impactful research within its areas of expertise, including gender-specific cancers such as gynecologic, breast, and prostate cancers as well as localized or locally advanced cancers of all types. The NRG NCORP focuses on cancer prevention and control, cancer care delivery, health disparities and patient reported outcomes.
NRG Oncology is primarily funded by grants from the National Cancer Institute, and its results are regularly published in peer-reviewed journals and presented at professional society meetings, many results having a direct and meaningful impact through improving the recommended care for those at risk or being treated for cancer.
NRG Oncology Foundation, Inc., was founded in 2012 in the Commonwealth of Pennsylvania as a joint venture of the NSABP Foundation, RTOG Foundation, and GOG Foundation. As one of five research networks funded by the NCI National Clinical Trials Network and seven Research Bases funded by the NCI Community Oncology Program, their network includes over 1,800 sites across the United States, Canada and across the world. For more information visit www.nrgoncology.org.